Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO Breast 2021 | The BCI prognostic model for late relapse breast cancer

John Bartlett, BSc, PhD, FRCPath, Ontario Institute for Cancer Research, Ontario, Canada, gives an overview of the Breast Cancer Index (BCI) prognostic model which can be used to predict the benefit from endocrine therapy for patients with HR+ breast cancer and late relapse. Data from the aTTom study (NCT00003678) of tamoxifen was used to train a cut point for the signature which could identify women who are at highest risk of late relapse and women at modest risk of late relapse. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.


John Bartlett, BSc, PhD, FRCPath, has participated in a consultancy role for Insight Genetics, Inc., BioNTech AG, Biotheranostics, Inc., Pfizer, Rna Diagnostics Inc., oncoXchange/MedcomXchange Communications Inc., Herbert Smith French Solicitors and OncoCyte Corporation; has participated in a scientific advisory board with MedcomXchange Communications Inc.; has received honoraria from NanoString Technologies, Inc., Oncology Education, Biotheranostics, Inc. and MedcomXchange Communications Inc.; has received research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technologies, Inc., Stratifyer GmbH and Biotheranostics, Inc.; has receive travel and/or accommodations expenses from Biotheranostics, Inc., NanoString Technologies, Inc., and Breast Cancer Society of Canada; has a patent for histone gene module predicts anthracycline benefit, PCT/CA2016/000247; discloses invention of A Molecular Classifier for Personalized Risk Stratification for Patients with Prostate Cancer, Date: 21/08/2019; and has applied for the following patents: Jan 2017: Methods and Devices for Predicting Anthracycline Treatment Efficacy, US utility – 15/325,472; EPO – 15822898.1; Canada – not yet assigned, Jan 2017: Systems, Devices and Methods for Constructing and Using a Biomarker, US utility – 15/328,108; EPO – 15824751.0; Canada – not yet assigned, Dec 2016: 95-Gene Signature of Residual Risk Following Endocrine Treatment, PCT/CA2016/000304, Dec 2016: Immune Gene Signature Predicts Anthracycline Benefit, PCT/CA2016/000305, June 2020: Use of Molecular Classifiers to Diagnose, Treat and Prognose Prostate Cancer, US Provisional 63/040.692.